Roman Necina
Chief Operating Officer at HOOKIPA PHARMA INC.
Net worth: 11 990 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jörn Aldag | M | 65 | 8 years | |
| Jan van de Winkel | M | 63 | 7 years | |
| Reinhard Kandera | M | 54 | 7 years | |
| Julie O'Neill | F | 58 | 6 years | |
| Mary Coelho | F | 62 | 1 years | |
| Tony Melckenbeek | M | - | - | |
| Klaus Orlinger | M | 46 | 12 years | |
| David Kaufman | M | 51 | 5 years | |
| Timothy Reilly | M | 50 | 2 years | |
| Norbert Riedel | M | 66 |
Austrian Academy of Sciences
 Austrian Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Austrian Academy of Sciences provides humanities and social science research services. The private company is based in Vienna, Austria. | 15 years |
| Victor Paulus | M | - | 6 years | |
| Karin Schaupp | M | 74 |
Austrian Academy of Sciences
Austrian Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Austrian Academy of Sciences provides humanities and social science research services. The private company is based in Vienna, Austria. | - |
| Malte Peters | M | 61 | 1 years | |
| Monika Henzinger | M | 58 |
Austrian Academy of Sciences
Austrian Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Austrian Academy of Sciences provides humanities and social science research services. The private company is based in Vienna, Austria. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Kelly | M | 67 | 4 years | |
| Daniel D. Pinschewer | M | 49 | 8 years | |
| Christine D. Baker | F | 58 | 5 years | |
| Jean-Charles Soria | M | 53 | - | |
| Christoph S. Lengauer | M | 59 | 4 years | |
| Katia Schlienger | M | 62 | 2 years | |
| Graziano Seghezzi | M | 55 | 10 years | |
| Sander J. van Deventer | M | 69 | 9 years | |
| Thomas D. Szucs | M | 64 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 years |
| Anders Lilja | M | - | 7 years | |
| Gerd Zettlmeissl | M | 68 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 10 years |
| Werner Lanthaler | M | 56 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 9 years |
| David Ebsworth | M | 69 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 8 years |
| Katherine Cohen | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 11 years |
| Matthew Beck | M | - | 4 years | |
| Gregory Glenn | M | 70 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 years |
| Igor Matushansky | M | 51 | 5 years | |
| Gwenaelle Kerforn | F | - | 3 years | |
| Nina Waibel | F | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 24 | 72.73% |
| Austria | 9 | 27.27% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Roman Necina
- Personal Network
